At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 68 enrolled
Drug / intervention
Deferiprone oral solutiondrug
Likely dose
Deferiprone oral solution 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)
In Brief
A Phase 3 clinical trial evaluating Deferiprone oral solution for Pantothenate Kinase-Associated Neurodegeneration. Completed, enrolled 68 participants across 4 sites in 4 countries.
Detailed Summary
Patients with PKAN will be treated with the iron chelator deferiprone for 18 months. Only patients who have completed the earlier study TIRCON2012V1 (NCT01741532), a double-blind placebo-controlled trial in which participants were randomized to receive either deferiprone or placebo for 18 months, are eligible to enroll.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Italy, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedJun 2014
Primary CompletionMar 2018
TodayJul 2026
First PostedJun 26, 2014
Enrollment StartJun 1, 2014
Primary CompletionMar 16, 2018
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 12.0 years ago
Interventions
Deferiprone oral solutiondrug
Deferiprone oral solution at a dosage of up to 15 mg per kilogram of body weight, twice a day